Skip to content
thestock.space

As of 6 Nov 2026, Lupin trades at 17.5× trailing earnings, below the industry P/E of 28.7×, and the shares are 21% below their 52-week high. Its ROCE of 28% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 19% and 131% a year over 3 years. Its dividend yield is 0.9%, and debt is 0.26× equity. It is a mid-cap company with a market cap of ₹90,914 Cr, ranked 10th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 0.5% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹1,985.50
Day high
₹1,996.90
Day low
₹1,968.20
Prev. close
₹1,988.00
Volume
4.3 L

Health check

4 good · 2 to check
  • ReturnsBehind

    −0.5% over a year, better than 1 of 7 peers.

  • Price tagCheaper

    P/E 17.5 vs industry 28.7.

  • GrowthStrong

    Sales +19.1%, profit +131.4% a year over 3 years.

  • ProfitabilityStrong

    ROCE 28.3% vs peer median 17.9%.

  • Balance sheetSolid

    Debt 0.26× equity, interest covered 17.7×, Piotroski 7 of 9.

  • Red flags1 to check

    Quarterly profit down 22.1% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Mid cap

₹90,914 Cr, #10 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹30,746 Cr · profit ₹5,206 Cr
Market cap
₹90,914 Cr
Mid cap
P/E
17.5
Industry 28.7
Price to book
3.78
Peers 4.99
Dividend yield
0.91%
ROE
23.9%
Peers 14.7%
ROCE
28.3%
Peers 17.9%
Debt to equity
0.26
Debt ₹6,180 Cr
EPS (TTM)
₹113.48
Face value ₹2
OPM (TTM)
28.9%
Net margin 16.9%
Sales growth
+11.1%
Latest quarter vs a year ago
Profit growth
−22.1%
Latest quarter vs a year ago
Price to sales
2.96
EV/EBITDA 10.4

Strengths and risks

Strengths

  • Return on equity of 23.9%.
  • Return on capital employed of 28.3%.
  • P/E of 17.5 against an industry P/E of 28.7.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Quarterly profit down 22.1% on a year ago.

Derived automatically from reported figures. Not a recommendation.

About Lupin

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics,…

Headquarters
Mumbai
Employees
26,021
Sector
Healthcare
ISIN
INE326A01037
Website
lupin.com

Price range

52 weeks

₹1,892.90₹2,529.50

Today

₹1,968.20₹1,996.90
Avg volume (3M)
7.8 L
1-year return
minus 0.5%
From 52-week high
minus 21.4%

Analyst consensus

36 analysts
HoldMean target ₹2,394.50 plus 20.4%

Target range, with today’s price

Low ₹1,800.00High ₹3,095.00

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
LUPINLupin1,988.10plus 0.01%90,91417.53.7828.3%23.9%28.9%19.1%131.4%0.91%minus 0.5%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Dec 25Mar 26Jun 26Sep 26
6,1647,1007,3928,2177,786
4,5224,8915,2215,7545,828
1,6412,2092,1712,4631,957
26.6%31.1%29.4%30.0%25.1%
165167455116214
91.8115120110106
299313447365486
–−427−131−87.9–
1,4161,5221,9282,0171,580
13.7%22.4%23.8%29.8%26.9%
1,2191,1761,4601,4151,155
26.6225.6731.8930.8925.14

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+19.1%
Profit CAGR 3Y
+131.4%
EPS CAGR 3Y
+131.3%
ROE
23.9%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
16,27019,65622,19227,488
–+20.8%+12.9%+23.9%
14,50015,86416,67819,294
1,7703,7925,5148,194
10.9%19.3%24.8%29.8%
82.272.4131870
240279271413
8819961,1691,376
−14.9−168−190−403
7162,4224,0156,873
37.5%20.1%17.7%22.1%
4301,9143,2825,333
–+345.1%+71.4%+62.5%
9.4141.8771.69116.44

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
9191.191.391.4
12,37414,19917,11222,357
4,5422,9225,4486,616
5,9506,7856,5549,300
22,95623,99729,20538,365
5,6785,5615,6146,255
1,033662465806
47.120170.263.6
1,9522,1793,0207,948
14,24615,39520,03623,292
22,95623,99729,20538,365

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1,8973,6483,0007,335
−1,287−1,712−4,172−3,865
−337−2,1841,732−846
273−2485602,624
−1,500−929−1,682−2,055
3982,7191,3185,280
−183−183−365−548

Shareholding pattern

Source: NSE filings
46.8%
promoters
  • Promoters46.84%
  • Public53.16%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202646.84%53.16%minus 0.01
30 Jun 202646.85%53.15%minus 0.01
31 Mar 202646.86%53.14%minus 0.03
31 Dec 202546.89%53.11%minus 0.01
30 Sep 202546.90%53.10%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you